Biomarker legislation is reshaping insurance and diagnostics policy across many US states, with more than 20 currently mandating coverage for biomarker testing under certain conditions. However, translating law into consistent practice remains complex. This session will bring together leaders from patient advocacy, diagnostics, legal policy, and industry coalitions to share real-world insights into implementation. Panelists will explore how states, payers, and laboratories are interpreting coverage mandates, navigating evidence requirements, appeals, and prior authorization, and uncovering practical challenges in aligning policy with operational reality. Attendees will gain a clear view of both the opportunities and potential pitfalls in biomarker legislation, leaving with actionable strategies for how stakeholders can collaborate to help ensure laws achieve their intended goal - improving patient access to precision testing in a sustainable, equitable, and affordable way.